NCT02798354

Brief Summary

The proposal will focus on 3 specific, high-risk, pediatric ambulatory diagnostic errors each representing a unique dimension of diagnostic assessment: evaluation of symptoms, evaluation of signs and follow-up of diagnostic tests. Adolescent depression (i.e. symptoms) affects nearly 10% of teenagers, is misdiagnosed in almost 75% of adolescents and causes significant morbidity. Pediatric elevated blood pressure (signs) is misdiagnosed in 74-87% of patients, often due to inaccurate application of blood pressure parameters that change based on age, gender and height. Actionable pediatric laboratory values (diagnostic tests) are potentially delayed up to 26% of the time in preliminary investigations and 7-65% in adults, leading to harm and malpractice claims. The investigators propose to conduct a multisite, prospective, stepped wedge cluster randomized trial testing a quality improvement collaborative (QIC) intervention within the American Academy of Pediatrics' Quality Improvement Innovation Networks (QuIIN) to reduce the incidence of pediatric primary care diagnostic errors. QuIIN is a national network of over 300 primary care practices, ranging from tertiary care academic medical centers to single practitioner private practices, interested in and experienced with QICs. Because many processes are likely to be common across diagnostic errors in outpatient settings, a multifaceted intervention, such as a QIC, has a high likelihood of success and broad applicability across populations. Preparatory inquiries to QuIIN primary care providers suggest high interest in reducing these 3 diagnostic errors and provider agreement with randomization to evaluate diagnostic error interventions. Practices will be randomized to one of three groups, with each group collecting retrospective baseline data on one error above, and then intervening to reduce that error during the first eight months. Each group will concurrently collect control data on an error they are not intervening on during those eight months. Following those eight months, the groups will continue intervening on their first error, begin intervening on the error they were a control site for, and begin collecting data on the third error for which they will be a control site for. Finally, in the final eight months, all groups will intervene on all three errors. A second wave of practices will be recruited to join the groups after eight months and will only intervene on two of the three errors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13,853

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

May 25, 2016

Completed
20 days until next milestone

First Posted

Study publicly available on registry

June 14, 2016

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2017

Completed
2.1 years until next milestone

Results Posted

Study results publicly available

December 16, 2019

Completed
Last Updated

December 16, 2019

Status Verified

December 1, 2019

Enrollment Period

2.4 years

First QC Date

May 25, 2016

Results QC Date

September 9, 2019

Last Update Submit

December 12, 2019

Conditions

Keywords

DepressionBlood PressureAnemias, Iron-DeficiencyStreptococcal InfectionsSexually Transmitted DiseasesLead Poisoning, Nervous System, ChildhoodThyrotropin

Outcome Measures

Primary Outcomes (3)

  • Number of Adolescents Diagnosed With Depression Seen in Well Child Visits

    Patients \>=11 years old with documentation of major depression or subsyndromal depression diagnoses in the medical record

    Collected Monthly (5-9 baseline months and 8-9 intervention months depending on the enrolled cohort)

  • Number of Patients With Elevated Blood Pressure Measured and Appropriately Acted on by Providers

    Systolic or Diastolic Blood Pressure \>= 90th percentile for age, gender and height or \>=120/80 in \>=3 years old patients at well child visits and at least one of: 1) provider repeated blood pressure, 2) clinic note mentions elevated blood pressure/hypertension 3) plan included recheck or evaluation of blood pressure, or 4) ordering laboratory or other studies to evaluate elevated blood pressure

    Collected Monthly (5-9 baseline months and 8-9 intervention months depending on the enrolled cohort)

  • Number of Patients With Abnormal Laboratory Results With Appropriate Actions Without Delay

    Documented action step for first positive within 30 days: 1. Hemoglobin (Hgb) less than 11 and mean corpuscular volume (MCV) less than 75 in 1 or 2 year old without documentation of beginning iron, sending iron studies or family conversation 2. Lead greater than 5 without documentation of family conversation on lead remediation or plan to retest Documented action step for first positive within 7 days: 1. Positive Gonorrhea, Chlamydia, Syphilis or Human immunodeficiency virus (HIV) test without documentation of antibiotics begun or referral to HIV specialist 2. Positive group A streptococcal throat culture with negative rapid group A streptococcal test without documentation of antibiotics begun or family conversation 3. Thyroid stimulating hormone (TSH) less than 0.5 or greater than 4.5 in greater than 1 year old without plan to repeat lab values or referral to endocrinologist

    Collected Monthly (5-9 baseline months and 8-9 intervention months depending on the enrolled cohort)

Secondary Outcomes (4)

  • Number of Adolescents With Mental Health Addressed During Their Well Child Visit

    Collected Monthly (5-9 baseline months and 8-9 intervention months depending on the enrolled cohort)

  • Number of Patients With Elevated Blood Pressures Measured and Blood Pressure Percentiles Documented in the Chart

    Collected Monthly (5-0 baseline months and 8-9 intervention months depending on the enrolled cohort)

  • Number of Patients With Elevated Blood Pressures Measured and Recognized by Provider

    Collected Monthly (5-9 baseline months and 8-9 intervention months depending on the enrolled cohort)

  • Number of Patients With Abnormal Laboratory Results Received and Recognized by Provider

    Collected Monthly (5-9 baseline months and 8-9 intervention months depending on the enrolled cohort)

Other Outcomes (3)

  • Percent of Clinics Reaching Pre-Determined Threshold for Providers With Laboratory Results Unread/Unacknowledged in Their Electronic Health Record (EHR) Inbox for More Than 72 Hrs

    Collected at 4 months

  • Percent of Clinics Reaching Pre-determined Threshold for Children Greater Than or Equal to 3 Yrs Old Receiving Blood Pressure Measurements at Triage for Well Child Visits

    Collected until 2 months

  • Percent of Clinics Reaching Predetermined Threshold for Adolescents Screened for Depression With Patient Health Questionnaire-9 Modified (PHQ-9M) During Well Child Visits

    Collected monthly for 8 months when practice is intervening on this topic

Study Arms (3)

Reduce Elevated Blood Pressure Errors First

EXPERIMENTAL

Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc.

Behavioral: Quality Improvement Collaborative

Reduce Depression Errors First

EXPERIMENTAL

Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis. Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc.

Behavioral: Quality Improvement Collaborative

Reduce Lab Related Errors First

EXPERIMENTAL

Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis. Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc.

Behavioral: Quality Improvement Collaborative

Interventions

1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams

Reduce Depression Errors FirstReduce Elevated Blood Pressure Errors FirstReduce Lab Related Errors First

Eligibility Criteria

Age26 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The investigators will include 30 primary care pediatric practices that are part of the American Academy of Pediatrics' QuIIN (Quality Improvement Innovation Networks) organization. The second wave will recruit 15 additional practices.
  • Practices must have sufficient volumes of adolescent well child visits (17 per month) and all well child visits (30 per month), and be able to query their EHR systems in order to be included in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

American Academy of Pediatrics

Elk Grove Village, Illinois, 60007, United States

Location

Related Publications (1)

  • Bundy DG, Singh H, Stein RE, Brady TM, Lehmann CU, Heo M, O'Donnell HC, Rice-Conboy E, Rinke ML. The design and conduct of Project RedDE: A cluster-randomized trial to reduce diagnostic errors in pediatric primary care. Clin Trials. 2019 Apr;16(2):154-164. doi: 10.1177/1740774518820522. Epub 2019 Feb 5.

MeSH Terms

Conditions

DepressionAnemia, Iron-DeficiencyStreptococcal InfectionsSexually Transmitted DiseasesLead Poisoning, Nervous System, Childhood

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorAnemia, HypochromicAnemiaHematologic DiseasesHemic and Lymphatic DiseasesIron DeficienciesIron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsCommunicable DiseasesGenital DiseasesUrogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsLead Poisoning, Nervous SystemHeavy Metal Poisoning, Nervous SystemNeurotoxicity SyndromesNervous System DiseasesLead PoisoningHeavy Metal PoisoningPoisoningChemically-Induced Disorders

Limitations and Caveats

Practices enrolled in a QIC are likely not representative of all practices. Appropriate actions broadly defined. No direct chart review verifications. No data on 11 practices who left the study. Quasi-random chart review strategy.

Results Point of Contact

Title
Dr. Michael Rinke
Organization
Children's Hospital at Montefiore and Albert Einstein College of Medicine

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 25, 2016

First Posted

June 14, 2016

Study Start

June 1, 2015

Primary Completion

October 31, 2017

Study Completion

October 31, 2017

Last Updated

December 16, 2019

Results First Posted

December 16, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations